Josep-Maria Ribera, MD, PhD, Germans Trias i Pujol University Hospital, Barcelona, Spain, discusses the preliminary results of the Phase II PONALFIL trial (NCT02776605) investigating ponatinib in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). In this study, patients were treated with ponatinib and standard chemotherapy, followed by consolidation and allogeneic stem cell transplantation. Ponatinib was only used as maintenance therapy for patients with persistence or reappearance of measurable residual disease (MRD). The complete response rate was 100% and the complete molecular response rate was 42%. The preliminary results of this trial showed a high short-term antileukemic efficacy with an acceptable toxicity profile, and showed that transplant is feasible. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Josep-Maria Ribera, has been a speaker, participated in advisory boards and received honoraria from Pfizer, AMGEN, Shire and Ariad; has participated in clinical trials with Pfizer, AMGEN and Ariad; and has received research support from AMGEN.